Skip to main content
SpringerLink
Log in

Medikamentöse Rezidivprophylaxe

  • Chapter
Book cover Interventionelle Gefäßtherapie

Zusammenfassung

Für die Entwicklung einer Rezidivstenose (Abb. 7.4.1) nach Angioplastie sind drei wesentliche Mechanismen verantwortlich [2,25]:

  • die Thrombozytenadhäsion und-aggregation mit Mediatorenfreisetzung

  • die Ausbildung einer neointimalen Hyperplasie sowie

  • das negative Remodelling

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 59.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. ACCORD Study Investigators (1994) Nitric oxide donors reduce restenosis after coronary angioplasty: the ACCORD Study. JACC 24 (Suppl.):59A

    Google Scholar 

  2. Alfke H, Böger RH, Bode-Böger SM (1996) Reste-nose nach perkutaner transluminaler Angioplastie: I. Ätiologie and klinische Bedeutung. VASA 25:13–20

    PubMed  CAS  Google Scholar 

  3. Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomized trials of antiplatelet therapy: L Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. II. Maintenance of vascular graft or arterial patency by anti-platelet therapy. BMJ 308:81–106, 159–168

    Article  Google Scholar 

  4. CAPRIE Steering Committee (1996) A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339

    Article  Google Scholar 

  5. Clowes AW, Karnovski MJ (1977) Supression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265:216–222

    Article  Google Scholar 

  6. ERASER Investigators (1999) Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 100:799–806

    Article  Google Scholar 

  7. Eriksen UH, Amtorp O, Bagger JP et al (1995) Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am Heart J 130:1–8

    Article  PubMed  CAS  Google Scholar 

  8. Faxon DP, Sanborn TA, Haudenschild CC et al (1984) Effect of antiplatelet therapy on restenosis after experimental angioplasty. Am J Cardiol 53: 72C–76C

    Article  PubMed  CAS  Google Scholar 

  9. Heiss HW, Just H, Middleton D et al (1990) Re-occlusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology 1990; 41:263–269

    Article  CAS  Google Scholar 

  10. Hess H, Müller-Fassbender H, Ingrisch H et al (1978) Verhütung von Wiederverschlüssen nach Rekanalisation obliterierter Arterien mit der Kathetermethode. Dtsch med Wschr 103:1994–1997

    Article  PubMed  CAS  Google Scholar 

  11. Kastrati A, Schuhlen H, Hausleiter J et al (1997) Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation 96: 462–467

    PubMed  CAS  Google Scholar 

  12. Mahler F, Schneider E, Gallino A et al (1987) Combination of suloctidil and anticoagulation in the prevention of reocclusion after femoro-popliteal PTA. VASA 16:381–385

    PubMed  CAS  Google Scholar 

  13. McNamara DB, Bedi B, Aurora H et al (1993) L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun 193: 291–296

    Article  PubMed  CAS  Google Scholar 

  14. Minar E, Ehringer H, Ahmadi R et al (1989) Platelet deposition at angioplasty sites and its relation to restenosis in human iliac and femoropopliteal arteries. Radiology 170:767–772

    PubMed  CAS  Google Scholar 

  15. Minar E, Ahmadi A, Koppensteiner R et al (1995) Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation 91: 2167–2173

    Article  PubMed  CAS  Google Scholar 

  16. Müller MR, Salat A, Stangl P et al (1997) Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78: 1003–1007

    Google Scholar 

  17. Nyamekye I, Costa D, Raphael M et al (1997) Thrombosis and restenosis after peripheral angioplasty: Does acute (111)indium-platelet accumulation predict angioplasty outcome? Eur J Vasc Endovasc Surg 13:388–393

    Article  PubMed  CAS  Google Scholar 

  18. O’Connor GT, Malenka DJ, Olmstead EM et al (1992) A meta-analysis of randomized trials of fish oil in prevention of restenosis following coronary angioplasty. Am J Prey Med 8:186–192

    Google Scholar 

  19. Okamoto S, Inden M, Setsuda M et al (1992) Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 123:1439–1444

    Article  PubMed  CAS  Google Scholar 

  20. Ranke C, Creutzig A, Luska G et al (1994) Controlled trial of high-versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. Clin Invest 72:673–680

    CAS  Google Scholar 

  21. Richter E-I, Zeitler E (1983) Percutaneous transluminal angioplasty: adjunct drug therapy. In: Dotter CT, Grüntzig AR, Schoop W, Zeitler E, eds. Per-cutaneous Transluminal Angioplasty. Springer, Berlin, Heidelberg, pp 84–90

    Chapter  Google Scholar 

  22. Rutherford RB, Becker GJ (1991) Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. Radiology 181:277–281

    PubMed  CAS  Google Scholar 

  23. Schneider E, Mahler F, Do D et al (1987) Zur Rezidivprophylaxe nach perkutaner transluminaler Angioplastie (PTA): Antikoagulation versus Ticlopidin. VASA 1987 (Suppl.) 20:355

    Google Scholar 

  24. Schomig A, Neumann FJ, Kastrati A et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084–1089

    Article  PubMed  CAS  Google Scholar 

  25. Schwartz SM, Reidy MA (1996) Restenosis: an assessment of factors important in arterial occlusion. In: Fuster V, Ross R, Topol EJ (eds) Atherosclerosis and coronary artery disease, pp 701–714

    Google Scholar 

  26. Schwartz L, Bourassa MG, Lespérance J et al (1988) Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 318:1714–1719

    Article  PubMed  CAS  Google Scholar 

  27. Schweizer J, Kirch W, Koch R et al (1998) Effect of High Dose Verapamil on Restenosis After Peripheral Angioplasty. JACC 31:1299–1305

    Article  PubMed  CAS  Google Scholar 

  28. Scott NA, Cipolla GD, Ross CE et al (1996) Identification of a potential role of the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 93:2178–2187

    Article  PubMed  CAS  Google Scholar 

  29. See J, Shell W, Matthews O et al (1987) Prostaglandin El infusion after angioplasty in humans inhibits abrupt occlusion and early restenosis. Adv Prostaglandin Thromboxane Leukot Res 17A:266–270

    PubMed  CAS  Google Scholar 

  30. Sekiya M, Funada J, Watanabe K et al (1998) Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 82:144–147

    Article  PubMed  CAS  Google Scholar 

  31. Study group on pharmacological treatment after PTA (1994) Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease: a prospective double-blind trial. Eur J Vasc Surg 8:83–88

    Article  Google Scholar 

  32. Tamai H, Katoh O, Suzuki S (1999) Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis Following Angioplasty Trial (TREAT). Am Heart J 138:968–975

    Article  PubMed  CAS  Google Scholar 

  33. Tardif JC, Cote G, Lespérance J et al (1997) Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 337: 365–372

    Article  PubMed  CAS  Google Scholar 

  34. Tepe G, Schott U, Erley CM et al (1999) Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis. Am J Roentgenol 172:1343–1346

    Article  CAS  Google Scholar 

  35. Topol EJ, Calif RM, Weisman HF et al (1994) Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 343:881–886

    Article  PubMed  CAS  Google Scholar 

  36. Tsuchikane E, Fukuhara A, Kobayashi T et al (1999) Impact of cilostazol on restenosis after per-cutaneous coronary balloon angioplasty. Circulation 100:21–26

    Article  PubMed  CAS  Google Scholar 

  37. Waksman R (1999) Late thrombosis after radiation - Sitting on a time bomb. Circulation 100:780–782

    Article  PubMed  CAS  Google Scholar 

  38. Weichert W, Meents H, Abt K et al (1994) Acetylsalicylic acid-reocclusion-prophylaxis after angioplasty (ARPA-Study). VASA 23:57–65

    PubMed  CAS  Google Scholar 

  39. White CW, Chaitman B, Knudtson ML et al (1991) Antiplatelet agents are effective in reducing the acute ischemic complications of angioplasty but do not prevent restenosis: results from the ticlopidine trial. Coronary Artery Disease 2.757–767

    Google Scholar 

  40. White GH, Liew SC, Waugh RC et al (1995)Early outcome and intermediate follow-up of vascular stents in the femoral and popliteal arteries without long-term anticoagulation. J Vasc Surg 21:270–279

    Article  PubMed  CAS  Google Scholar 

  41. Zeitler E, Reichold J, Schoop W et al (1973) Einfluß von Acetylsalicylsäure auf das Fri hergebnis nach perkutaner Rekanalisation arterieller Obliterationen nach Dotter. Dtsch med Wschr 98:1285–1288

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. E. Minar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kardiologische Fachklinik Herz- und Kreislaufzentrum, Rotenburg an der Fulda, Heinz-Meise-Str. 100, Rotenburg a.d.F., 36199, Germany

    Christian Vallbracht

  2. LVA Aggertalklinik, Am Sondersiefen 18, Engelskirchen, 51766, Germany

    Franz-Josef Roth

  3. Abteilung für Angiologie, Dominikus-Krankenhaus Düsseldorf, Am Heerdter Krankenhaus 2, Düsseldorf, 40549, Germany

    Andreas L. Strauss (Chefarzt) (Chefarzt)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Minar, E. (2002). Medikamentöse Rezidivprophylaxe. In: Vallbracht, C., Roth, FJ., Strauss, A.L. (eds) Interventionelle Gefäßtherapie. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57540-2_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57540-2_36

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-63296-9

  • Online ISBN: 978-3-642-57540-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation